Development and Commercialization of Licensed Products. 3.1 COMMERCIALIZATION.
Development and Commercialization of Licensed Products. Except with respect to the activities being conducted by the Parties under the Research Programs and Optimization Programs, as between Licensee and Arvinas, following the first exercise of an Option for an Exclusive Target pursuant to Section 3.2 above, (i) Licensee shall have sole responsibility for, and bear all costs for, researching, developing and commercializing Licensed Products in the Field in the Territory; and (ii) subject to the obligations expressly set forth herein, Licensee shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products in the Field in the Territory.
Development and Commercialization of Licensed Products. Immune Design shall have the sole responsibility and the sole discretion to research, develop and commercialize Licensed GLA Product(s) in the Immune Design Exclusive Field and in the *** Field in that part of the Territory that is outside the IDRI Territory.
Development and Commercialization of Licensed Products. As between Licensee and Kineta,
Development and Commercialization of Licensed Products. As between the Parties, Kxxxxx shall have sole control, authority, and discretion over the research, development, manufacture and commercialization of Licensed Products throughout the world, subject to Section 3.3. If Kxxxxx xxxxx any Licensed Product as part of a bundle, or as part of a combination therapy where Kxxxxx has the right to sell and set the price of the other component of the combination therapy, then Kineta shall not disproportionately discount, in a manner inconsistent with the relative value of the components of such combination therapy or bundle, the pricing of the Licensed Product relative to the other components. Kxxxxx shall not use any Licensed Product as a loss leader.
Development and Commercialization of Licensed Products. Except with respect to the activities being conducted by the Parties under the Research Programs, as between GNE and Immunocore (i) GNE shall have sole responsibility for and bear all costs for, researching, developing and commercializing Licensed Products; and (ii) GNE shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products. On an Exclusive Target-by-Exclusive Target basis, GNE agrees to use Diligent Efforts to research, develop and commercialize at least one Licensed Product that binds to an HLA-presented antigen derived from each Exclusive Target within the Field in the Territory.
Development and Commercialization of Licensed Products. As between the Parties, Poseida shall have sole control, authority, and discretion over the research, development, manufacture and commercialization of Licensed Products in the Field in the Territory, subject to Section 3.3. ***Certain Confidential Information Omitted
Development and Commercialization of Licensed Products. The Company undertakes to develop Licensed Products in the Field, for application in the following end-user categories: Over-The-Counter Products Prescription Medical Food Products Prescription Drug Products. The Company shall be responsible, at its own cost, for the development, for the conduct of all clinical research required as well as for the commercialization of the Licensed Products in the Licensed Field. The Company agrees that the Licensed Products to be commercialized shall always conform to the following specifications: o The concentration of phospholipids contained in the Licensed Products shall be at [REDACTED: Concentration]. The Company must ensure that the above-concentrations of phospholipids are stable within the Licensed Products [REDACTED: Period]. CONFIDENTIAL TREATMENT REQUESTED BY NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. SCHEDULE 7.1
Development and Commercialization of Licensed Products. Except with respect to the activities being conducted by the Parties under the Research Programs, as between GNE and AFMD (i) GNE shall have sole responsibility for, bear all costs for, researching, developing and commercializing Licensed Products; and (ii) GNE shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products. On an Exclusive Target-by-Exclusive Target basis, GNE agrees to use Diligent Efforts to research, develop and commercialize in one of the US, EU or Japan at least one Licensed Product that binds to each Exclusive Target.
Development and Commercialization of Licensed Products. The Company undertakes to develop Licensed Products in the Field, for application in the following end-user categories: • Over-The-Counter Products • Prescription Medical Food Products • Prescription Drug Products. The Company shall be responsible, at its own cost, for the development, for the conduct of all clinical research required as well as for the commercialization of the Licensed Products in the Licensed Field. The Company agrees that the Licensed Products to be commercialized shall always conform to the following specifications: • The concentration of phospholipids contained in the Licensed Products shall be [REDACTED: Concentration]. • The Company must ensure that the above-concentrations of phospholipids are stable within the Licensed Products for [REDACTED: Period]. SCHEDULE 7.1 CLAIMS RELATING TO THE LICENSED INTELLECTUAL PROPERTY [REDACTED: Claims]
